[1] |
Liu CY, Chen KF, Chen PJ. Treatment of liver cancer. Cold Spring Harb Perspect Med, 2015; 5, a021535. doi: 10.1101/cshperspect.a021535 |
[2] |
Thomas HE, Mercer CA, Carnevalli LS, et al. mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma. Sci Transl Med, 2012; 4, 139ra84. |
[3] |
Morrison AH, Byrne KT, Vonderheide RH. Immunotherapy and prevention of pancreatic cancer. Trends Cancer, 2018; 4, 418−28. doi: 10.1016/j.trecan.2018.04.001 |
[4] |
Luo YJ, Yao YX, Wu P, et al. The potential role of N7-methylguanosine (m7G) in cancer. J Hematol Oncol, 2022; 15, 63. doi: 10.1186/s13045-022-01285-5 |
[5] |
Gao ZJ, Xu JY, Zhang ZP, et al. A comprehensive analysis of METTL1 to immunity and stemness in Pan-Cancer. Front Immunol, 2022; 13, 795240. doi: 10.3389/fimmu.2022.795240 |
[6] |
Ma JY, Han H, Huang Y, et al. METTL1/WDR4-mediated m7G tRNA modifications and m7G codon usage promote mRNA translation and lung cancer progression. Mol Ther, 2021; 29, 3422−35. doi: 10.1016/j.ymthe.2021.08.005 |
[7] |
Chen Z, Zhang Z, Ding W, et al. Expression and potential biomarkers of regulators for M7G RNA modification in gliomas. Front Neurol, 2022; 13, 886246. doi: 10.3389/fneur.2022.886246 |
[8] |
Schabath MB, Welsh EA, Fulp WJ, et al. Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma. Oncogene, 2016; 35, 3209−16. doi: 10.1038/onc.2015.375 |
[9] |
St Paul M, Ohashi PS. The Roles of CD8 T Cell Subsets in Antitumor Immunity. Trends Cell Biol, 2020; 30, 695-704. doi: 10.1016/j.tcb.2020.06.003IF:4.996Q2B3 |
[10] |
Sangro B, Chan SL, Meyer T, et al. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. J Hepatol, 2020; 72, 320−41. doi: 10.1016/j.jhep.2019.10.021 |